The Japan Association for Thoracic Surgery carried out a nationwide academic survey of Japan in 2010, and the results show the outcomes of the main diseases treated with thoracic surgery. These are excellent results in comparison with those from Western countries. Here, perioperative mortality means mortality within one month of surgery, and hospital mortality is mortality of patients who could not be discharged from hospital.
|Main disease||No. of patients||Perioperative mortality rate||Hospital mortality rate|
|Primary lung cancer||33,112||0.4%||0.8%|
|Metastatic lung tumor||6,748||0.1%||0.1%|
|Inflammatory lung disease||3,140||0.1%||0.2%|
|Benign lung tumor||840||0%||0.12%|
|Chest wall tumor||684||0%||0.4%|
The Japan Lung Cancer Society, the Japan Association for Chest Surgery, and the Japan Respiratory Society jointly run the Japanese Joint Committee of Lung Cancer Registry, and they publish outcomes of surgery based on national totals. In 2010, the national totals of the outcomes of cases of lung cancer resection performed in 2004 were published. Data were obtained from 253 (41.8%) of the 605 facilities certified for training in respiratory organ surgery, with a total of 11,663 cases. The five-year survival rate for all cases was 69.6%, and the rate was 63.0% for males and 80.9% for females. By clinical stage, the five-year survival rate was: IA, 82.0%; IB, 66.1%; IIA, 54.5%; IIB, 46.4%; IIIA, 42.8%; IIIB, 40.3%; and IV, 31.4%. By pathological stage, the five-year survival rate was: IA, 86.8%; IB, 73.9%; IIA, 61.6%; IIB, 49.8%; IIIA, 40.9%; IIIB, 27.8%; and IV, 27.9%.